Home > News > First Protein-Bound Nanoparticle Breast Cancer Drug
January 7th, 2005
First Protein-Bound Nanoparticle Breast Cancer Drug
Researchers at Lynn Sage Comprehensive Breast Center played a significant role in the U.S. Food and Drug Administration (FDA) approval of ABRAXANE(TM) (paclitaxel protein bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer.
"This approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel.
Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014
European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014
Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014
Tuning light to kill deep cancer tumors: Nanoparticles developed at UMass Medical School advance potential clinical application for photodynamic therapy October 15th, 2014
Physicists build reversible laser tractor beam October 20th, 2014
Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014
1980s aircraft helps quantum technology take flight October 20th, 2014
Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014